Stay updated on Lumateperone Monotherapy in Bipolar Depression Global Clinical Trial

Sign up to get notified when there's something new on the Lumateperone Monotherapy in Bipolar Depression Global Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Lumateperone Monotherapy in Bipolar Depression Global Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    6 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study record related to the efficacy and safety evaluation of ITI-007 in patients with Bipolar I or Bipolar II disorder experiencing a major depressive episode.
    Difference
    0.1%
    Check dated 2024-06-06T14:39:29.000Z thumbnail image
  7. Check
    21 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for study participants, specifying that eligible individuals are males or females aged 18-75 with a clinical diagnosis of Bipolar I or Bipolar II disorder experiencing a current major depressive episode. Previously, no information was provided under the Participation Criteria section.
    Difference
    14%
    Check dated 2024-05-22T21:02:40.000Z thumbnail image
  8. Check
    43 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:02:16.000Z thumbnail image

Stay in the know with updates to Lumateperone Monotherapy in Bipolar Depression Global Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Lumateperone Monotherapy in Bipolar Depression Global Clinical Trial page.